BACKGROUND This is the first report of an ROS1-CENPW fusion gene in pancreatic malignancies.CASE SUMMARY A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital.Genetic t...BACKGROUND This is the first report of an ROS1-CENPW fusion gene in pancreatic malignancies.CASE SUMMARY A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital.Genetic testing revealed the presence of the ROS1-CENPW fusion gene,a rare fusion gene that has not been previously reported in the field of pancreatic cancer.The patient received crizotinib plus AG(albumin paclitaxel plus gemcitabine)chemotherapy.After treatment,the patient’s condition stabilized,and her prognosis was good.CONCLUSION The ROS1-CENPW gene treatment regimen used in this case is an excellent treatment option that provides new hope for patients with advanced pancreatic cancer and similar genetic mutations.To date,owing to the rarity of the ROS1-CENPW fusion gene,our team has encountered only a single case.Therefore,the efficacy of crizotinib plus AG chemotherapy in patients with pancreatic acinar cell carcinoma harboring the ROS1-CENPW fusion gene requires further validation.展开更多
Pancreatic carcinomas with acinar differentiation are rare,accounting for 1%-2% of adult pancreatic tumors; they include pancreatic acinar cell carcinoma(PACC),pancreatoblastoma,and carcinomas of mixed differentiation...Pancreatic carcinomas with acinar differentiation are rare,accounting for 1%-2% of adult pancreatic tumors; they include pancreatic acinar cell carcinoma(PACC),pancreatoblastoma,and carcinomas of mixed differentiation. Patients with PACC have a prognosis better than pancreatic ductal adenocarcinomas but worse than pancreatic neuroendocrine tumors. Reports of overall survival range from 18 to 47 mo. A literature review on PACCs included comprehensive genomic profiling and whole exome sequencing on a series of more than 70 patients as well as other diagnostic studies including immunohistochemistry. Surgical resection of PACC is the preferred treatment for localized and resectable tumors. The efficacy of adjuvant treatment is unclear. Metastatic PACCs are generally not curable and treated with systemic chemotherapy. They are moderately responsive to chemotherapy with different regimens showing various degrees of response in case reports/series. Most of these regimens were developed to treat patients with pancreatic ductal adenocarcinomas or colorectal adenocarcinomas. Review of PACC's molecular profiling showed a number of gene alterations such as: SMAD4,BRAF,BRCA2,TP53,RB1,MEN1,JAK-1,BRCA-1,BRCA-2,and DNA mismatch repair abnormalities. PACCs had multiple somatic mutations with some targetable with available drugs. Therefore,molecular profiling of PACC should be an option for patients with refractory PACC.展开更多
BACKGROUND Multiple primary malignant tumors are two or more malignancies in an individual without any relationship between the neoplasms.In recent years,an increasing number of cases have been reported.However,concom...BACKGROUND Multiple primary malignant tumors are two or more malignancies in an individual without any relationship between the neoplasms.In recent years,an increasing number of cases have been reported.However,concomitant primary gastric and pancreatic cancer reported a relatively small incidence,involving no pancreatic acinar cell carcinoma reports.Here,we present the first case of concomitant pancreatic acinar cell carcinoma and gastric adenocarcinoma.CASE SUMMARY A 69-year-old male presented to our department with a history of vomiting,epigastric pain,and weight loss.Imaging revealed space-occupying lesions in the stomach and the tail of the pancreas,respectively.The patient underwent laparo-scopic radical gastrectomy and pancreatectomy simultaneously.The pathologies of surgical specimens were completely different:The resected gastric specimen was moderate to poorly differentiated adenocarcinoma,whereas the pancreatic tumor was consistent with acinar cell carcinoma.The patient was treated with six cycles of oxaliplatin and S-1 chemotherapy.As of March 2021,the patient was healthy without any recurrence or metastasis.After thoroughly reviewing the literature on simultaneous pancreatic and gastric cancers at home and abroad,we discussed the clinical characteristics of these rare synchronous double cancers.Most of the cases had undergone surgery and adjuvant chemotherapy,and all of the cases were pathologically confirmed by the postoperative specimen.CONCLUSION Synchronous pancreatic acinar cells and gastric adenocarcinoma can occur and should be considered when tumors are found in these organs.展开更多
文摘BACKGROUND This is the first report of an ROS1-CENPW fusion gene in pancreatic malignancies.CASE SUMMARY A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital.Genetic testing revealed the presence of the ROS1-CENPW fusion gene,a rare fusion gene that has not been previously reported in the field of pancreatic cancer.The patient received crizotinib plus AG(albumin paclitaxel plus gemcitabine)chemotherapy.After treatment,the patient’s condition stabilized,and her prognosis was good.CONCLUSION The ROS1-CENPW gene treatment regimen used in this case is an excellent treatment option that provides new hope for patients with advanced pancreatic cancer and similar genetic mutations.To date,owing to the rarity of the ROS1-CENPW fusion gene,our team has encountered only a single case.Therefore,the efficacy of crizotinib plus AG chemotherapy in patients with pancreatic acinar cell carcinoma harboring the ROS1-CENPW fusion gene requires further validation.
文摘Pancreatic carcinomas with acinar differentiation are rare,accounting for 1%-2% of adult pancreatic tumors; they include pancreatic acinar cell carcinoma(PACC),pancreatoblastoma,and carcinomas of mixed differentiation. Patients with PACC have a prognosis better than pancreatic ductal adenocarcinomas but worse than pancreatic neuroendocrine tumors. Reports of overall survival range from 18 to 47 mo. A literature review on PACCs included comprehensive genomic profiling and whole exome sequencing on a series of more than 70 patients as well as other diagnostic studies including immunohistochemistry. Surgical resection of PACC is the preferred treatment for localized and resectable tumors. The efficacy of adjuvant treatment is unclear. Metastatic PACCs are generally not curable and treated with systemic chemotherapy. They are moderately responsive to chemotherapy with different regimens showing various degrees of response in case reports/series. Most of these regimens were developed to treat patients with pancreatic ductal adenocarcinomas or colorectal adenocarcinomas. Review of PACC's molecular profiling showed a number of gene alterations such as: SMAD4,BRAF,BRCA2,TP53,RB1,MEN1,JAK-1,BRCA-1,BRCA-2,and DNA mismatch repair abnormalities. PACCs had multiple somatic mutations with some targetable with available drugs. Therefore,molecular profiling of PACC should be an option for patients with refractory PACC.
文摘BACKGROUND Multiple primary malignant tumors are two or more malignancies in an individual without any relationship between the neoplasms.In recent years,an increasing number of cases have been reported.However,concomitant primary gastric and pancreatic cancer reported a relatively small incidence,involving no pancreatic acinar cell carcinoma reports.Here,we present the first case of concomitant pancreatic acinar cell carcinoma and gastric adenocarcinoma.CASE SUMMARY A 69-year-old male presented to our department with a history of vomiting,epigastric pain,and weight loss.Imaging revealed space-occupying lesions in the stomach and the tail of the pancreas,respectively.The patient underwent laparo-scopic radical gastrectomy and pancreatectomy simultaneously.The pathologies of surgical specimens were completely different:The resected gastric specimen was moderate to poorly differentiated adenocarcinoma,whereas the pancreatic tumor was consistent with acinar cell carcinoma.The patient was treated with six cycles of oxaliplatin and S-1 chemotherapy.As of March 2021,the patient was healthy without any recurrence or metastasis.After thoroughly reviewing the literature on simultaneous pancreatic and gastric cancers at home and abroad,we discussed the clinical characteristics of these rare synchronous double cancers.Most of the cases had undergone surgery and adjuvant chemotherapy,and all of the cases were pathologically confirmed by the postoperative specimen.CONCLUSION Synchronous pancreatic acinar cells and gastric adenocarcinoma can occur and should be considered when tumors are found in these organs.
